MAPT and Alzheimer disease: Indeed, a large cross‐sectional ADRC study shows that CSF VE‐Cadherin levels are elevated in cognitively unimpaired patients with preclinical AD and correlates positively with CSF ADRD biomarkers including Aβ42/40, ptau‐181, total‐tau, and neurofilament light chain (NfL).139